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Objective: To examine medication adherence and persistence among COPD patients during
their last year of life.
Data source: National VA databases were used to identify patients who had COPD and died
between 1999 and 2003.
Study design: We examined use of inhaled corticosteroids (ICS), long acting b2 agonists
(LABA), methylxanthines (MTX), and anticholinergics (AC), alone and in combination. Medi-
cation possession ratios (MPR) were compared between regimens by quarterly periods
using General Estimating Equations (GEE). Medication persistence was examined in mono-
therapy users with KaplaneMeier survival analysis and extended Cox proportional hazard
models.
Principal findings: Only half of the identified patients in the COPD cohort (5913 of 11,376)
used any medications. Among 5913 patients, overall mean (SD) MPR was 0.44 (0.32) during
the last year of life. A positive linear trend in MPR was observed across quarterly periods in
AC users (bZ 0.014, p< 0.0001), and was highest for MTX users (bZ 0.11, p< 0.0001). Of
3436 on monotherapy only, 40% discontinued medication within 30 days, and 70% discontin-
ued within 90 days. MTX users were less likely to discontinue (HRZ 0.714, pZ 0.012) than
reference (AC) group.was performed: Center for Management of Complex Chronic Care (CMC3), Hines VA Hospital, Hines,
at Chicago.
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526 E. Jung et al.Conclusion: COPD patients in their last year of life tended to use respiratory medications
sporadically. Further research is needed to qualify whether minor differences in MPR
between regimens reflect behavioral differences related to regimen or reflect refill policy
and MPR calculation technique.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth
leading cause of death and is anticipated to be the third-
most-common cause of death by 2020.1,2 Comorbidity is
highly prevalent in COPD patients and 84% of patients have
one or more comorbidity factors.3 The annual per capita
health care expenditure for people with COPD is more than
two timeshigher than that for peoplewithoutCOPD.4Despite
the high prevalence of morbidity and mortality associated
with COPD, patients with COPD often do not receive
adequate palliative care.5 The symptoms of COPD are
primarily managed through medication. There is limited
research on compliance and discontinuation of medications
by COPD patients towards the end of life. Discontinuation of
medication may occur for a variety of reasons, such as
reduced symptomatology or due to the complexity of treat-
ment regimens.6 Various factors such as age, adverse events,
comorbidities, concomitant medications, dosing frequen-
cies, aswell as capacity to perform tasks, havebeen shown to
influence compliance and persistence.7,8 However, decisions
involving medication management at the end of life are
complicated by many factors including the nature and
severity of the illness, efficiency of life sustaining treatment,
age and the emotions and values of the patient and their
family.9
Most studies have found that patients with more severe
disease tend to be more persistent or adherent with their
medications.6,8,10,11 In COPD, studies of medication persis-
tence and compliance tend to observe that early discontin-
uation occurs among a large number of COPD patients.8
Breekveldt-Postma et al. found that approximately 50% of
the patients discontinued treatment with inhaled cortico-
steroid within 6 months and only 18% were persistent for one
year.10 Cramer et al. found that persistence with COPD
medications was low across all types of medication, ranging
from 57 to 96 mean days until discontinuation over a year of
observation time.8 Bender et al. investigated the use of flu-
catisone propionate/salmeterol and found that only 9% of
patients continued to refill over one year.6
Little is known about the medication adherence and
persistence of COPD patients in the last year of life.
Although some literature deals with the end of life care in
COPD patients, no study has focused on the medication use
patterns. Measuring medication compliance and persis-
tence and investigating explanatory factors can help to
understand patterns of care towards the end of life and
better inform patient management. Thus, the overall aim
of this study was to examine the patterns of respiratory-
related medications in patients with COPD in their last year
of life. The specific objectives of this study were 1) to
determine whether medication compliance changes over
time and differs between drug classes during last year oflife; 2) to compare extent of medication persistence and
the length of time of persistence between drug classes over
the last 12 months of life.
Methods
A retrospective cohort study of patients with COPD in the
Veterans Affairs (VA) was conducted using VA inpatient,
outpatient files of the National Patient Care Database
(NPCD), and pharmacy data from Pharmacy Benefit
Management (PBM). The VA Beneficiary Identification
Records Locator System (BIRLS) and National Death Index
(NDI) were used to identify patients known to be deceased.
VA-Medicare databases were also used to get hospitalization
information on patients who were Medicare eligible within
the study cohorts. Four categories of COPD-related medica-
tions were investigated: 1) inhaled corticosteroids (ICS); 2)
long acting b2 agonists (LABA); 3) methylxanthines (MTX);
and 4) anticholinergics (AC), alone and in combination.
Cohort identification
Patients were identified for inclusion in the study cohort
based on ICD-9/10 codes of inpatient and outpatient
databases and the Beneficiary Identification Records
Locator System (BIRLS) between fiscal years (FY) 1999 and
FY2003. The study cohort included patients aged 45e99
who had at least one ICD-10 code (J42eJ44) in 1999 and
beyond, or at least one International Classification of
Disease, Ninth Revision (ICD-9), diagnostic code for non-
specified bronchitis (490.0e490.9), chronic bronchitis
(491.0, 491.1, 491.2, 491.8, 491.9), emphysema (492.0,
492.8) or chronic airway obstruction (496.9) before 1999.
Patients who were deceased during FY 1999 to 2003 were
identified using the date of death in BIRLS data and were
included in this study.
Using VA-inpatient data and VA-Medicare database,
patients who were hospitalized for more than 60 days
during their last year of life were identified and excluded
from the study cohort. The study cohort was limited to
patients who used at least one prescription for COPD
treatment based on the National Drug Codes (NDC) during
the 12 month period before their date of death.
Study period
The 360-day period prior to date of death was used to
measure medication adherence and persistence. The index
date of the study period was calculated as 360 days before
the date of death in VA-NDI linked COPD patient data. The
360 days prior to date of death was divided into four 90-day
intervals. Hospitalization days in any health care facility
were subtracted from the total days comprising the
COPD medication adherence and persistence 527denominator for the adherence and persistence calculation
for each quarter. This provided a truer representation of
each individual’s adherence and persistence, but assumes
that veterans did not take VA outpatient prescribed medi-
cation while they were hospitalized.
Measures
Medication adherence (compliance) is defined as the
consistency and accuracy with which a patient follows
a pharmacy regimen. The medication possession ratioVA – National Death Index
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Table 1 Characteristics of COPD patients according to medication use.
No COPD medication
(nZ 5463)
COPD medication
(nZ 5913)
p-value
Age [mean, (SD)] 73.07 (10.84) 72.01 (10.15) <0.0001
Male [n, (%)] 5375 (98.39) 5836 (98.70) 0.169
Ethnicity [n, (%)] <0.0001
White 3877 (70.97) 4137 (69.96)
Black 655 (11.99) 552 (9.34)
Native American, Asian and other 931 (17.04) 1224 (20.70)
Mail order services [n, (%)] e e 2964 (50.13) N/A
Hospitalization during last year of life [n, (%)] 2715 (49.70) 4005 (67.73) <0.0001
Inpatient hospitalization [n, (%)] 1774 (32.47) 2785 (47.10) <0.0001
VA-Medicare [n, (%)] 1297 (23.74) 1865 (31.54) <0.0001
Hospice care [n, (%)] 702 (12.85) 1019 (17.23) <0.0001
Charlson comorbidity index [mean, (SD)] 2.52 (3.03) 3.54 (3.03) <0.0001
0e1 2694 (49.31) 1700 (28.75) <0.0001
2e5 1991 (36.45) 3065 (51.83)
6 778 (14.24) 1148 (19.41)
Baseline COPD composite medication e e 2577 (43.58) N/A
Baseline ICS e e 643 (10.87)
Baseline LABA e e 216 (3.65)
Baseline MTX e e 333 (5.63)
Baseline AC e e 1852 (31.32)
Palliative care 109 (2.00) 175 (2.96) 0.001
Emergency visit [n, (%)] <0.0001
0 3837 (70.24) 3433 (58.06)
1e3 1279 (23.41) 1880 (31.79)
4 347 (6.35) 600 (10.15)
COPD emergency visit [n, (%)] <0.0001
0 5075 (92.90) 4901 (82.89)
1 298 (5.45) 719 (12.16)
2 90 (1.65) 293 (4.96)
Primary care visit [n, (%)] <0.0001
0 2062 (37.74) 713 (12.06)
1e3 1483 (27.15) 2050 (34.67)
4 1918 (35.11) 3150 (53.27)
Specialist visit [n, (%)] <0.0001
0 4372 (80.03) 3729 (63.06)
1e2 714 (13.07) 1301 (22)
3 377 (6.90) 883 (14.93)
Condition [n, (%)]
Depression 569 (10.42) 838 (14.17) <0.0001
Myocardial infarction (MI) 277 (5.07) 464 (7.85) <0.0001
Congestive heart failure (CHF) 1061 (19.42) 1707 (28.87) <0.0001
Peripheral vascular disease 551 (10.09) 865 (14.63) <0.0001
Cerebrovascular disease 486 (8.90) 640 (10.82) 0.0006
Dementia 203 (3.72) 141 (2.38) <0.0001
Rheumatologic disease 94 (1.72) 143 (2.42) 0.0092
Peptic ulcer disease 178 (3.26) 265 (4.48) 0.0008
Mild liver disease 154 (2.82) 171 (2.89) 0.8154
Moderate/severe liver disease 76 (1.39) 60 (1.47) 0.6807
Diabetes without chronic complications 1051 (19.24) 1435 (24.27) <0.0001
Diabetes with chronic complications 189 (3.46) 237 (4.01) 0.1237
Hemiplegia/paraplegia 24 (0.44) 33 (0.56) 0.3701
Renal disease 364 (6.66) 541 (9.15) <0.0001
Any malignancy, including lymphoma and leukemia 1238 (22.66) 1891 (31.98) <0.0001
Metastatic solid tumor 487 (8.91) 710 (12.01) <0.0001
AIDS 21 (0.38) 25 (0.42) 0.7472
AC, anticholinergics; AIDS, acquired immune deficiency syndrome; COPD, chronic obstructive pulmonary disease; ICS, inhaled corti-
costeroid; LABA, long acting b2 agonists; MTX, methylxanthines; SD, standard deviation; VA, veterans affairs.
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COPD medication adherence and persistence 529potential to exceed 1 when employing this approach,
because the denominator could be less than 360 days (or 90
days for each quarter) when subtracting hospitalization
days from study period.
Medication persistence is defined as the accumulation of
time from initiation to discontinuation of therapy. Persis-
tence was measured by the total duration of continuous
prescription refills. Patients were considered non-persistent
if they failed to refill within a 30 day grace period after the
expected end date of the previous prescription. Since this
study was designed to evaluate the medication patterns at
the end of life, the treatment was defined as discontinued
when patients were not persistent. Time to discontinuation
for the one year study periodwas calculated as the time from
the index date to an unacceptable gap (i.e. gap exceeded 30
days). Analysis of persistence was restricted to patients who
used a single medication during last year of life.
Covariates
Covariates in adjusted models included age, race, time of
diagnosis, the Charlson comorbidity index, diagnosis of
depression, baseline COPD-related medication use atTable 2 Medication possession ratios for COPD medication user
Variable N Mean SD
MPR over 12 months
Any COPD meds 5913 0.436 0.321
ICS 2290 0.354 0.268
LABA 1002 0.340 0.255
Methylxanthine 669 0.521 0.316
Anticholinergic 5240 0.384 0.287
First quarter MPR
Any COPD meds 3945 0.611 0.331
ICS 1378 0.546 0.311
LABA 555 0.528 0.299
Methylxanthine 508 0.705 0.312
Anticholinergic 3293 0.560 0.312
Second quarter MPR
Any COPD meds 3779 0.646 0.323
ICS 1350 0.576 0.304
LABA 579 0.546 0.302
Methylxanthine 470 0.715 0.304
Anticholinergic 3217 0.594 0.307
Third quarter MPR
Any COPD meds 4066 0.646 0.328
ICS 1457 0.578 0.312
LABA 625 0.568 0.294
Methylxanthine 464 0.754 0.289
Anticholinergic 3487 0.592 0.310
Fourth quarter MPR
Any COPD meds 4310 0.658 0.341
ICS 1530 0.578 0.321
LABA 705 0.573 0.300
Methylxanthines 478 0.739 0.307
Anticholinergics 3723 0.606 0.326
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteindex date (LABA, ICS, MTX, AC), hospitalization inside
and treatment outside the VA, Emergency Room (ER)
visits, the use of mail order services, primary care visits,
specialist visits, hospice care and palliative care
utilization.
Statistical analysis
Demographic characteristics of COPD medication users
were compared to non-medication users. Chi-square
statistics were used to compare proportions between
dichotomous or categorical variables and independent
sample t tests were used to compare continuous variables.
With mean MPR as the dependent variable, General Esti-
mating Equation (GEE) models were used to investigate
trends in medication adherence across four quarter periods
and the trend differences between drug classes. The four
COPD drug classes alone and in combination resulted in 15
potential drug regimens. Those regimens with 50 or more
patients were entered into models, which resulted in 12
regimens.
Anticholinergic medications were used as the reference
group for contrasting differences in MPR across drugs (nZ 5913).
Median Q1 Q3 Min. Max.
0.357 0.164 0.693 0 1.869
0.273 0.130 0.536 0 1.040
0.255 0.131 0.513 0 1.050
0.526 0.214 0.806 0 1.050
0.306 0.140 0.598 0 1.284
0.611 0.333 0.933 0 1.844
0.533 0.300 0.833 0 1.184
0.500 0.315 0.778 0 1.111
0.800 0.494 0.989 0 1.154
0.535 0.311 0.856 0 1.311
0.667 0.344 0.962 0 2.111
0.564 0.333 0.856 0 1.200
0.544 0.322 0.811 0 1.125
0.817 0.488 1.000 0 1.184
0.600 0.333 0.889 0 1.422
0.667 0.341 0.967 0 2.186
0.567 0.333 0.878 0 1.263
0.577 0.333 0.831 0 1.139
0.867 0.549 1.000 0.011 1.184
0.589 0.333 0.889 0 1.447
0.678 0.349 0.978 0 2.333
0.553 0.329 0.867 0 1.200
0.556 0.333 0.833 0 1.200
0.823 0.500 1.000 0.012 1.200
0.600 0.333 0.911 0 1.763
roid; LABA, long acting b2 agonists.
530 E. Jung et al.classes. Because the dependent variable was continuous,
the identity link function and normal distribution were
used. MPRs were compared between drug classes/regimens
using unadjusted and adjusted models. We tested for
possible multicolinearity between covariates using the
variance inflation factor (VIF). Quasi-likelihood under the
independence model criterion (QIC) was used for model
selection.
Unadjusted KaplaneMeier survival curves were used to
evaluate the extent of medication persistence over the last
12 month of life between drug classes. Statistically signifi-
cant differences in medication persistence across drug
classes were identified using Wilcoxon tests. Prior to using
the Wilcoxon test, the proportional hazards assumption was
tested by assessing the correlation between the Schoenfeld
residuals for covariates and ranking individual survival
time. The extended Cox proportional hazards model was
used to compare medication persistence across COPD drug
classes, adjusting for covariates. The dependent variable
was the time to discontinuation for each medication. A
stepwise selection method was used to include covariates
in the model, with a p-value of at least 0.25 as a cutoff
point. All analysis was performed using SAS version 9.1 and
STATA version 9 with the probability of Type I error set at
aZ 0.05.Table 3 Medication possession ratios, adjusted estimates using
Parameter Estimate SE
Intercept 0.405 0.021
Quarter 0.018 0.002
ICS 0.032 0.013
LABA 0.017 0.026
MTX 0.097 0.020
ICSþ LABA 0.031 0.019
ICSþ AC 0.010 0.007
LABAþ AC 0.013 0.014
MTXþ AC 0.089 0.013
ICSþ LABAþ AC 0.030 0.010
ICSþMTXþ AC 0.061 0.013
ICSþ LABAþMTXþ AC 0.101 0.017
Other 0.089 0.022
Baseline medication 0.153 0.006
Race (black) 0.046 0.009
Race (others) 0.008 0.007
Age 0.001 0.000
CCI 2e3 0.000 0.004
CCI 4 0.003 0.005
Mail order services 0.050 0.006
Hospice 0.007 0.007
Length of stay 0.018 0.007
Depression 0.003 0.008
ER visits 1e3 0.006 0.004
ER visits 4 0.008 0.006
Primary care
visits 1e3
0.055 0.005
Primary care
visits 4
0.056 0.005
AC, anticholinergics (reference category); CCI, Charlson comorbidity i
corticosteroids; LABA, long acting b2 agonists; MTX, methylxanthinesResults
Patient population
Of the 17,536 patients who were diagnosed with COPD and
had died during 1999 to 2003, 12,945 patients were iden-
tified as ever hospitalized for at least one day in their last
year of life. Of these, 6160 patients were hospitalized more
than 15 days during one quarter period or more than 60
days during the last year of life, and thus were excluded.
Among 11,376 COPD patients, 5913 subjects had used any
COPD medication during their last year of life. 2477
patients (42%) who used two or more COPD medications,
and 3436 single COPD medication users who were included
in the persistence study (Fig. 1).
Table 1 shows patient characteristics by use of COPD
medication. The mean age of COPD medication users
(nZ 5913) was 72.0 (SDZ 10.2) years which is slightly
younger than no COPD medication users. During the last
year of life, COPD medication users utilized health care
facilities more than non-COPD medication users
(p< 0.0001). The percentage of COPD medication users
with any ER visits, any primary care visits and any hospice
care were significantly higher than those of non-COPD
medication users. Mean Charlson comorbidity index scoresGEE.
95% CI p-value
0.364 0.447 <0.0001
0.014 0.021 <0.0001
0.058 0.006 0.0158
0.069 0.034 0.5136
0.058 0.135 <0.0001
0.068 0.006 0.0988
0.004 0.024 0.1648
0.013 0.040 0.3263
0.064 0.115 <0.0001
0.010 0.049 0.0035
0.035 0.087 <0.0001
0.067 0.134 <0.0001
0.047 0.132 <0.0001
0.142 0.165 <0.0001
0.065 0.028 <0.0001
0.005 0.022 0.2424
0.001 0.000 0.0055
0.007 0.007 0.9878
0.007 0.013 0.5962
0.039 0.062 <0.0001
0.007 0.021 0.3498
0.005 0.031 0.0056
0.011 0.018 0.6521
0.015 0.003 0.1766
0.004 0.020 0.2017
0.046 0.064 <0.0001
0.046 0.065 <0.0001
ndex; CI, confidence intervals; ER, emergency room; ICS, inhaled
; SE, standard error.
Table 4 Risk of medication discontinuation (hazard
ratio).
Variable Hazard
ratio
95% CI p-value
ICS 1a 1.34 1.01 1.79 0.046
LABA 1 1.75 1.14 2.69 0.011
MTX 1 1.47 1.00 2.18 0.053
ICS 2 1.04 0.89 1.21 0.648
LABA 2 0.97 0.73 1.28 0.808
MTX 2 0.64 0.49 0.83 0.001
Baseline medication 1.26 1.15 1.37 <0.0001
Race (black) 1.20 1.06 1.37 0.005
CCI 2e3 0.97 0.91 1.02 0.218
CCI 4 0.96 0.89 1.03 0.222
Mail order services 0.84 0.77 0.92 <0.0001
COPD ER visit 1 0.86 0.77 0.96 0.009
COPD ER visit 2 1.14 0.98 1.32 0.086
Primary care visit 1e3 0.72 0.67 0.76 <0.0001
Primary care visit 4 0.76 0.72 0.81 <0.0001
AC, anticholinergics (reference category); CCI, Charlson
comorbidity index; CI, confidence intervals; COPD ER, chronic
obstructive pulmonary disease related emergency room visit;
ICS, inhaled corticosteroids; LABA, long acting b2 agonists; MTX,
methylxanthines.
a 1Z First time interval, 0e25 days from index date; 2Z
second time interval, 25e360 days from index date.
COPD medication adherence and persistence 531were higher in COPD medication users (3.54 3.03) as
compared to non-COPD medication users (2.52 3.03).
Medication compliance
Mean MPRs for patients on any COPD medications and COPD
medications by class are presented in Table 2. Methylxan-
thines had the highest mean MPR over the one year period.
Overall, mean MPRs for COPD medications increased quar-
terly. The number of patients who used any COPD medi-
cations was slightly lower at the second quarter (nZ 3779)
and increased at the last two quarters (3rd quarter
nZ 4066, 4th quarter nZ 4310).
Based on the lowest QIC test score, the unstructured
linear GEE model was selected as the final model to test the
MPR trend change over time and MPR differences between
drug classes. The unadjusted GEE model demonstrated an
increasing linear trend in MPR across four quarters in last
year of life (bZ 0.0141, p< 0.0001). MPRs for ICS only were
significantly lower than the referent anticholinergics
only group (p-valueZ 0.03). MPRs were significantly
higher than the referent group for groups on MTX only,
ICSþ AC, MTXþ AC, ICSþ LABAþ AC, ICSþMTXþ AC,
ICSþ LABAþMTXþ AC (all p-values< 0.0001).
The variance inflation factors (VIF) of all covariates
included in adjustedGEEmodelwere less than 10, alleviating
concerns about multicolinearity in the adjusted GEE model.
After adjustment for covariates, the overall MPR trends did
not change from the unadjusted GEE model (Table 3). The
time slope coefficient showed a linear trend towards
increases in MPR (bZ 0.0178, p< 0.0001) that was similar to
the unadjusted model (bZ 0.0141). The intercept of the AC
reference group was 0.4054, which was slightly lower than
that of the unadjusted model (bZ 0.4874). The MPR trends
for the LABA, ICSþ LABA, ICSþ AC and LABAþ AC groups
were not significantly different from the reference group.
Any baseline medication use at the index date (bZ 0.1533,
p< 0.0001), the use of mail order services (bZ 0.0502,
p< 0.0001), length of stay inside and outside the VA health
care facilities (bZ 0.0183, pZ 0.0056) and any primary care
visits (bZ 0.055,p< 0.0001)were positively associatedwith
a higher MPR. African American race (bZ0.0542,
p< 0.0001) and age (bZ0.0008, pZ 0.0055) were asso-
ciated with significantly lower MPRs.
Medication persistence
The overall mean time to discontinuation in patients who
had used any COPD medication was 94.2 (SDZ 102.6) days.
Patients who had used LABA had the shortest mean time to
discontinuation (79.4 days, SDZ 90.5) and MTX users had
the longest mean time to discontinuation (125.6 days,
SDZ 128.7). Approximately 30% of any COPD single medi-
cation users persisted on their medication until their date
of death. LABA showed the highest percentage of discon-
tinuation (78.7%) and MTX and AC (55.7e68.6%) were more
persistent than ICS users and LABA users (63.3e78.7%) at
the date of death.
Based on KaplaneMeier survival analyses to estimate
persistence on monotherapy among users of the four drug
classes, MTX group had a higher medication persistencerate than the other three groups, while the LABA group had
the lowest persistence in most follow up period (Fig. 2). At
25 days and 90 days from the index date, significant drops
were observed. The proportional hazard assumption was
violated. Significant differences in survival curves between
drug classes were observed using Wilcoxon test
(pZ 0.0259). Thus, the extended Cox proportional hazard
model was employed.
The 360-day period prior to death was divided into two
different time intervals to hold the proportional hazard
assumption. The first time interval was 0e25 days, and the
second time interval was 25e360 days. In the adjusted
analysis (Table 4), the AC reference group was more
persistent than monotherapy users of other drug classes
during the first time interval. For the second interval,
methylxanthine users, e.g. MTX2 group, showed signifi-
cantly greater persistence than most of the other classes
(HRZ 0.64, 95% CI: 0.49, 0.83). Estimates of medication
persistence for the unadjusted and adjusted extended Cox
proportional hazard models were similar.
The risk of discontinuation increased with the use of
baseline medication at index date by 25.7% (HRZ 1.257,
p< 0.001). African Americans had a 1.2 times higher risk of
discontinuation than Caucasians, who served as the refer-
ence group (HRZ 1.204, pZ 0.0048). The use of mail order
services (HRZ 0.842, p< 0.001) and any primary care visits
(primary care 1e3 HRZ 0.715, p< 0.0001: primary care 4
HRZ 0.764, p< 0.0001) were associated with a lower risk
of discontinuation. Patients who had seven or less ER visits
due to COPD (HRZ 0.86, pZ 0.0009) had a lower risk of
discontinuation than patients who did not visit ER during
the last year of life.
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Figure 2 Comparison of persistence among single COPD medication users by drug class. 21.3% (LABA) e 44.3% (MTX) of any COPD
single medication users persisted on their medication until their date of death. AC, anticholinergics; ICS, inhaled corticosteroid;
LABA, long acting b2 agonists; MTX, methylxanthines.
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This is one of the first studies to examine respiratory medi-
cation use towards the endof life in COPDpatients, andwhile
the results provide some insight, they are challenging to
interpret, particularly given that they are derived from
administrative data. We found that COPD patients in their
last year of life often do not use medications and tended to
use respiratory medications sporadically. Only half of the
initially identified COPD cohort (5913 of 11,376) used any
medications in their last year of life. COPD medication users
were hospitalized more often, had more comorbid condi-
tions, andhadmore emergency department andother health
care visits than non-COPD medication, which suggests that
non-medication users may have been healthier than medi-
cation users in some respects, although everyone in the
cohort was in their last year of life.
MPRs generally did not reach 0.80 for any medication
regimen, which implies that patients may have received
sub-optimal clinical benefit from their medications.
However, a significant improvement in MPR was observed
across four quarters of the last year of life. Patients may be
more compliant with their medication to alleviate their
respiratory distress as COPD patients experience more
breathlessness at the end of life.12,13 There was a signifi-
cant difference in MPR across four COPD drug classes. The
mean MPR for methylxanthines was higher than other COPD
drug classes, which is consistent with a previous study
which showed patients were significantly more compliant
with theophyline that inhaled corticosteroids and cromo-
lyn.14 Theophylline is typically prescribed when symptoms
are not well-controlled. Generally, in last two decades, the
clinical use of methylxanthines as first-line bronchodilators
has declined due to its narrow therapeutic range and side
effects.15,16 Further research is needed to qualify whether
minor differences in MPR between regimens reflect
behavioral differences related to regimen or reflect refill
policy and MPR calculation technique.As methylxanthines were the only orally administered
medication among four COPD drug classes, it is possible
that elderly veterans had more difficulty using inhaled
medications.15,17 A previous study reported that there is
a stigma to using inhaled medications in public,18 however,
social stigma may not be an issue among patients in their
last year of life. The most obvious explanation for higher
MPRs for methylxanthines was that a 90-day supply was
allowed for methylxanthines, while inhaled medications
were dispensed in 30-days supply amounts.
Results from GEE models indicated that the number of
drugs in a regimen was positively related to higher
compliance in the last year of life. In simple terms, the
more drugs used, the greater the compliance in the last
year of life. It is possible that patients were more compliant
with multiple medications because they possibly had more
severe disease and needed to use medications as prescribed
in order to alleviate their symptoms. In the adjusted GEE
model, the use of mail order services, length of stay in
hospitals and primary care visits were positively associated
with higher rate of compliance. Mail order services may
facilitate the ability of elderly patients with impairments to
get the drugs they need.19 It is also conceivable that more
frequent health care utilization, e.g. physician office visits,
during the last year of life contributed medication
compliance, as patients who visited primary care regularly
may communicate with their physician and manage their
therapy better.18 Length of hospital stay was associated
with higher medication compliance, but this might not
represent the true association between MPR and length of
stay because hospitalization days were excluded from the
denominator in the calculation of MPR. The association
between length of stay as a covariate and the mean MPR
might be artificially inflated by the design of the study.
An interesting hypothesis generating result that
warrants further investigations was that African Americans
showed lower regimen compliance compared to Cauca-
sians. The race covariate may be confounded with
COPD medication adherence and persistence 533socioeconomic factors such as income, insurance status,
education level, occupation and social status in community.
Problematically, race is a data element that relies on self-
report, and is not consistently reported in VA data. Further
research is needed to determine if there is a real associa-
tion between race and medication compliance towards the
end of life.
The percentage of single COPD medication users who
were persistent with their medications at 9 month prior to
death was 33.8% (95% CI: 21.28e36.3%), which declined to
30.9% (95% CI: 31.6e36.3%) at the date of death. This rate
of persistence was similar to previous studies which showed
that 15e63% of patients continued for six month and
dropped to 7e53% at 12 month follow up.8 Specifically,
29.5% of ICS users persisted on their medications at 6 month
prior to death and after 12-months, ICS persistence was
27.3% in our study. In a previous study, 50% of ICS users
continued treatment for 196 days and only 17.6% continued
ICS treatment for one year.10 Another study found that only
8.8% of patients on fluticasone propionate/salmeterol
combination therapy continuously refilled their prescrip-
tions for a 12-month follow up period after the index
prescription date.6 One explanation is that patients at the
end of life may be more persistent because they had more
severe disease, and required more frequent use of medi-
cation for symptomatic relief.
This study has several limitations which are related to
the nature of patient cohort and data used, study design,
variable definitions and the operationalization of adher-
ence and persistence. The study cohort was composed of
primarily elderly male veterans. It is unclear to what extent
any of the results are generalizable to other age groups,
conditions, medication types, and populations. For the
measure of medication compliance and persistence,
patients’ prescription acquisition behaviors using the PBM
data are measured instead of the measure of patient’s
actual medication consumption behaviors. Patients may fill
the prescriptions but not consume them. The index date of
the study was calculated from the death of date; in
contrast, most studies that measure medication compliance
create an index date based on the date of the first
prescription. Among COPD medication users, over 40%
patients had been taking one or more respiratory-related
medications prior to the index date of study period. Thus,
depending on when patients started their first prescription,
medication adherence could be overestimated or under-
estimated. Therefore, this may not truly reflect patterns of
medication use in COPD patients, even though the study
design is sufficient to know the trend in patterns of medi-
cation use in the last year of life. In the calculation of MPR
on a quarterly basis, incident cases could enter into the
quarter at any time during the quarter, while the denomi-
nator for each patient was not adjusted for the time that
specific individual was in the quarter. We conducted
sensitivity analysis by excluding incident cases and found
the results to be robust. Days where a patient was hospi-
talized were subtracted from the denominator of the MPR
calculation, which may overestimate compliance if the
patient was not compliant in hospital.
In spite of the noted limitations, this study is the first,
to our knowledge, that examines patterns of medication
use at the last year of life in COPD patients. It providessome initial insight into the level of medication compli-
ance and persistence among veterans in the terminal
stages of their life. Indicators of quality of care have
received less attention in COPD than conditions such as
cancer. To improve the care of older veterans, the
Veterans Health Administration (VHA) has implemented
innovative end of life care programs and has tried to
extend these programs throughout all VA institutions.20,21
This study raises a number of issues about possible sub-
optimal use of respiratory-related medications among
COPD patients that could be illuminated through qualita-
tive research methods that would involve interviews with
patients and clinicians.
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